Compare GSM & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSM | PHAR |
|---|---|---|
| Founded | 2015 | 1988 |
| Country | United Kingdom | Netherlands |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 964.9M | 1.1B |
| IPO Year | 2015 | 2020 |
| Metric | GSM | PHAR |
|---|---|---|
| Price | $4.19 | $17.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 1.3M | 17.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.36 | $10.04 |
| Revenue Next Year | $17.85 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.04 | $7.79 |
| 52 Week High | $5.74 | $21.34 |
| Indicator | GSM | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 60.59 |
| Support Level | $4.10 | $17.25 |
| Resistance Level | $4.54 | $17.60 |
| Average True Range (ATR) | 0.22 | 0.64 |
| MACD | 0.03 | 0.16 |
| Stochastic Oscillator | 56.25 | 97.43 |
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's business segments include North America- Silicon, North America -Silicon Alloys; Europe Manganese; Europe Silicon Metals; Europe -Silicon Alloys, South Africa Silicon Metals, South Africa-Silicon Alloys, and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.